SABCS 2024

To Omit or Not to Omit: Rethinking SNL Biopsy

More testing - more surgery?

Challenging the first line treatment and chemotherapy - what is our first line treatment of choice in the future?

Practice changing combinations, treatment beyond progression and the art of medicine

CDK4/6i and ADC therapy for HER2+ and many more ADC options to come!

FASCINATE-N – GS1-04

PATINA – GS2-12

Ambivalent feelings about immunotherapy, but reassuring data for BRCA testing!

GeparDouze – GS3-05

CamRelief – GS3-06

OlympiA GS1-09

New data on CDK4/6i, oral SERDs and combinations, and evaluations

RW OS CDK4/6i – PS2-03

EMBER-3 – GS1-01

ADAPT – GS3-04

Exciting updates on OlympiA

BRCA-mut population - impact of surgery & OlympiA - update analysis

Time to limit postmastectomy radiotherapy indications

From the ZEST study to the german SURVIVE study

Survival benefit for patients with risk-reducing surgery

The beginning of the end of sentinel lymph nodes

Who need anthracyclines for node-negative HR+ BC

Risk reducing mastectomy in patients with BRCA mutation

ctDNA in follow-up - not for everyday clinical practice, but for clinical trials

Older EBC patients should also undergo surgery

Olaparib after (neo)adjuvant chemotherapy

My highlights of SABCS 2024

No axillary surgery necessary in selected patients

Targets are important in EBC

Who needs chemotherapy?

Phase 2 neoadjuvant study with HER3 DXd

Fine-tuning of chemotherapy in node-negative luminal HR+/HER2- patients

Equivalence to chemotherapy with the combination of anti-HER2+, ET and palbociclib

Neo-adjuvant monitoring with MRT & US can reduce therapy duration

Is Margetuximab better than trastuzumab?

Fascinating data from Shanghai

Atezolizumab does not improve EFS in TNBC

Biomarker analysis from the A-Brave trial

KEYNOTE-522 Interim analysis 4: Biomarkers

Population BRCA-mut - impact de la chirurgie & OlympiA - analyse actualisée

Equivalencia a la quimioterapia con la combinación de anti-HER2+, ET y palbociclib

Analisi dei biomarcatori nello studio A-Brave

Jaka chemioterapia u chorych na raki ER+/HER2- bez zajęcia węzłów chłonnych?

I bersagli sono importanti nella EBC

Czas na ograniczenie wskazań do radioterapii po mastektomii

OlympiA

I miei punti di forza di SABCS 2024

Étude de phase 2 néoadjuvante avec HER3 DXd

Studio neoadiuvante di fase 2 con HER3 DXd

Improving patient management in metastatic BC trough app feedback

HER2-targeted therapy: quality of life in focus

Efficacy data of EMBER-3

EMBER-3

New SERD in phase-3-trial & CDK4/6 inhibitor in HR+ MBC

Comparison of all CDK4/6 in combination with AI in the US Real-Word Setting

CDK4/6i more equal than not

CDK4/6 inhibitor + ET is the best start for HR+ Patients

Abstract Nr. 1: Imlunestrant

Targeting endocrine pathways is superior to Chemo in high-risk MBC patients

Optimizing 1st line treatment with T-DXd followed HP in HER2+ mBC

Significant and clinical relevant benefit of the addition of palbociclib as maintenance therapy in ER+ / HER2+ ABC

Practice changing results for ER+/HER2+ patients

CDK4/6 inhibitors effective also in luminal HER2+ cancers

DESTINY-Breast 12: Quality of life

CDK4/6 inhibitor in HER2+ metastatic BC

HER2DX might optimize 1st line in HER2+ mBC

CDK4/6 + HER2-targeted therapy without chemo for triple positive BC

Endocrine combination therapy for triple positive BC

Dati di efficacia di EMBER-3

Inhibitory CDK4/6 skuteczne również w rakach luminalnych HER2+

Il targeting delle vie endocrine è superiore alla CT nelle pazienti MBC ad alto rischio

Nouveau SERD en phase 3 d'essai & Inhibiteur CDK4/6 dans le MBC HR+

Beneficio significativo y clínicamente relevante de la adición de palbociclib como terapia de mantenimiento en ER+ / HER2+ ABC

Optimización del tratamiento de 1ª línea con T-DXd seguido de HP en CMM HER2+.

HER2DX podría optimizar la 1ª línea en el CMM HER2+.